Corvus Pharmaceuticals (CRVS) Interest Expenses (2015 - 2026)
Corvus Pharmaceuticals' (CRVS) quarterly Interest Expenses came in at $924000.0 in Q1 2026, up 63.25% year-on-year from $566000.0 in Q1 2025, and up 4763.16% quarter-over-quarter from $19000.0 in Q4 2025.
Corvus Pharmaceuticals (CRVS) Interest Expenses (2015 - 2026) Analysis & Trends
Corvus Pharmaceuticals' Interest Expenses history runs 12 years deep, the most recent figure standing at $924000.0 for Q1 2026.
- On a quarterly basis, Interest Expenses rose 63.25% year-over-year to $924000.0 in Q1 2026; TTM through Mar 2026 was $924000.0, a 63.25% increase from a year earlier, with the FY2025 full-year figure at $102.1 million, up 12.78% from the prior year.
- Interest Expenses grew to $924000.0 in Q1 2026 per CRVS's latest filing, from $19000.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $1.1 million in Q1 2024 and bottomed at -$1.3 million in Q4 2024.
- The 5-year median for Interest Expenses is $459000.0 (2023), against an average of $394058.8.
- Biggest YoY gain for Interest Expenses was 134.2% in 2024; the steepest drop was 374.62% in 2024.
- Year by year, Interest Expenses stood at $430000.0 in 2022, then advanced by 7.21% to $461000.0 in 2023, then sank by 374.62% to -$1.3 million in 2024, then jumped by 101.5% to $19000.0 in 2025, then surged by 4763.16% to $924000.0 in 2026.
- Per Business Quant, the three latest CRVS Interest Expenses figures stand at $924000.0 (Q1 2026), $19000.0 (Q4 2025), and $566000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -42,141.15 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 32.89 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 16.81 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 420.30 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 28.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 1.17 Bn |
| 10 | Corvus Pharmaceuticals | 1.23 Bn | 1.23 Bn | - | 924,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 924,000.00 |
| Mar 31, 2026 | 924,000.00 |
| Dec 31, 2025 | 19,000.00 |
| Dec 31, 2025 | 19,000.00 |
| Sep 30, 2025 | 566,000.00 |
| Sep 30, 2025 | 566,000.00 |
| Jun 30, 2025 | 172,000.00 |
| Jun 30, 2025 | 172,000.00 |
| Mar 31, 2025 | 566,000.00 |
| Mar 31, 2025 | 566,000.00 |
| Dec 31, 2024 | -1.27 Mn |
| Dec 31, 2024 | -1.27 Mn |
| Sep 30, 2024 | 358,000.00 |
| Sep 30, 2024 | 358,000.00 |
| Jun 30, 2024 | 717,000.00 |
| Jun 30, 2024 | 717,000.00 |
| Mar 31, 2024 | 1.08 Mn |
| Mar 31, 2024 | 1.08 Mn |
| Dec 31, 2023 | 461,000.00 |
| Dec 31, 2023 | 461,000.00 |